BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18317963)

  • 1. Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells.
    Zhang Y; Zhang Y
    Cancer Invest; 2008; 26(3):230-6. PubMed ID: 18317963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
    Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
    Furukawa J; Wraight CJ; Freier SM; Peralta E; Atley LM; Monia BP; Gleave ME; Cox ME
    Prostate; 2010 Feb; 70(2):206-18. PubMed ID: 19790231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells.
    Ohtani M; Numazaki M; Yajima Y; Fujita-Yamaguchi Y
    Biosci Trends; 2009 Aug; 3(4):131-8. PubMed ID: 20103837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against insulin-like growth factor-I receptor, on the growth of colon cancer cells.
    Zamri N; Masuda N; Oura F; Yajima Y; Nakada H; Fujita-Yamaguchi Y
    Biosci Trends; 2012 Dec; 6(6):303-12. PubMed ID: 23337790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis.
    Jenkins PJ; Khalaf S; Ogunkolade W; McCarthy K; David T; Hands RE; Davies D; Bustin SA
    Endocr Relat Cancer; 2005 Dec; 12(4):891-901. PubMed ID: 16322329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers.
    Miyamoto S; Nakamura M; Shitara K; Nakamura K; Ohki Y; Ishii G; Goya M; Kodama K; Sangai T; Maeda H; Shi-Chuang Z; Chiba T; Ochiai A
    Clin Cancer Res; 2005 May; 11(9):3494-502. PubMed ID: 15867252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205.
    Li JC; Li R
    Cancer Res; 2007 Sep; 67(18):8856-64. PubMed ID: 17875727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.
    Kusada Y; Morizono T; Matsumoto-Takasaki A; Sakai K; Sato S; Asanuma H; Takayanagi A; Fujita-Yamaguchi Y
    J Biochem; 2008 Jan; 143(1):9-19. PubMed ID: 17956902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.